Testing a new cancer drug for advanced solid tumors

Plain-English translation of NCT07705334 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is a first-in-human trial of , a new type of cancer medication given as a daily pill. The study is designed to find the safest and most effective dose of this medication, and to see how well it works against several types of advanced cancers that have progressed despite standard treatment.

Many patients with advanced cancers don't respond well enough to existing treatments or cannot tolerate them. This trial is testing a new approach that may help patients whose cancers have stopped responding to standard therapies.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with advanced or metastatic solid cancer that has progressed despite standard treatment or you cannot tolerate standard treatments
you have at least one measurable tumor that can be seen on imaging
your cancer type is one of those listed in the study (such as triple negative breast cancer, lung cancer, colon cancer, pancreatic cancer, or others)
you have a life expectancy of at least 3 months and are in good enough overall health to participate

You likely don't qualify if…

you are currently taking other cancer treatments or investigational medications
you have serious heart disease or uncontrolled high-risk cardiovascular conditions
you have an active untreated infection or certain viral infections such as hepatitis B or C
you are pregnant, breastfeeding, or unable to use effective contraception for 90 days after the last dose
you have had major surgery within the past 4 weeks or have significant lung problems

What participation looks like

You would take the medication by mouth once daily as a tablet. The study has two phases: first, the dose is slowly increased in small groups to find the safest amount, then in the second phase, more patients receive the medication at the dose found to be safe and potentially effective. Throughout the study, you would have regular visits for blood tests, imaging scans, tumor biopsies, and check-ins to monitor how you are tolerating the medication and whether your cancer is responding.

AI-generated summary from trial data · Jul 18, 2026 · Not medical advice

Trial locations(3 sites)

United States

SCRI at HCA HealthONE, Denver, Colorado

The University of Texas MD Anderson Cancer Center, Houston, Texas

NEXT Oncology, San Antonio, Texas